Previous 10 | Next 10 |
2024-04-07 04:06:09 ET Ocugen (NASDAQ: OCGN) stock price has been one of the best-performing companies in Wall Street this year. It has jumped by more than 218% in 2024, beating some of the best-known brands like Nvidia and Amazon. This surge has boosted its total market cap to over $46...
2024-04-06 06:13:00 ET 3 Top Strategies to Trade Options With Penny Stocks in 2024 Trading penny stocks through options presents a dynamic avenue for investors looking to enhance their portfolios with high-potential, yet affordable securities. The intersection of options trading and p...
2024-04-05 10:56:25 ET More on Ocugen Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues Ocugen slips as accounting errors force restatements Ocugen shares make gains after US court dismisses class action lawsuits Seeking ...
Established Low Dose as Safe and Tolerable Dose in Current OCU410 Clinical Trial DSMB Approval to Proceed with Medium Dose Cohort Dosing Malvern, Pa., April 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on dis...
2024-04-02 19:00:11 ET Image source: The Motley Fool. Ocugen (NASDAQ: OCGN) Q4 2023 Earnings Call Apr 02, 2024 , 8:30 a.m. ET Operator Continue reading For further details see: Ocugen (OCGN) Q4 2023 Earnings Call Transcript
2024-04-02 11:19:08 ET More on Ocugen Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues Ocugen shares make gains after US court dismisses class action lawsuits Ocugen hits a 52-week high after decision to lower quorum requirement...
2024-04-02 08:37:57 ET More on Pre-market losers & stocks. Hut 8 Mining Corp. (HUT) Q4 2023 Earnings Call Transcript From Bull To Bear: Recent Events Drove Me To Exit My Position In HUT 8 Hut 8 Post-Merger Comprehensive Thesis: JCapital Research Might Be Right ...
Received alignment with FDA for broad retinitis pigmentosa (RP) indication in Phase 3 clinical trial of OCU400—first gene therapy program to receive a broad indication for RP. OCU400 Phase 3 clinical trial expected to commence in April 2024. Regenerative Medicine Advanced Therapy (...
Established Low Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial DSMB Determination to Proceed with Medium Dose Cohort Dosing MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused o...
MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to...
News, Short Squeeze, Breakout and More Instantly...
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and va...
2024-07-11 08:45:00 ET It hasn't been a stellar year so far for biotech companies. The industry, as measured by the SPDR S&P Biotech ETF , is up just 4% since January, significantly lagging the S&P 500 's nearly 17% gain. Of course, it's not hard to find stocks that have...